Yesterday, Cue Biopharma (CUE) announced a clinical trial collaboration with pharma giant Merck (MRK) to test CUE-101 in combination with Keytruda.

Shares promptly rallied above $22 on heavy volume, pushing our gains north of 100% since our entry.

Typically, I’d recommend taking some profits off the table at this point. Especially in a biotech that’s supposed to report data before the end of June.

But I’m letting my position ride.

Why? Because shares could ultimately be worth as much as $150.

Here are all the details…

Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user. 

By doing so, you agree to receive periodic research updates from DTR and only DTR.

We will never rent, sell or share your info.